Epidermal growth factor receptor (EGFR) mutations are common in NSCLC and have made EGFR-targeting drugs like osimertinib a cornerstone of treatment. Immune checkpoint inhibitors have also ...

HUTCHMED announced significant findings from the SACHI Phase III study, which investigated the combination of savolitinib and osimertinib in treating patients with locally advanced or metastatic ...

The savolitinib and osimertinib combination demonstrates promising efficacy in patients who have progressed on prior EGFR inhibitor therapy. The findings highlight the potential of this novel ...

After disease progression on osimertinib and other therapies, the patient began amivantamab monotherapy. Within six weeks, his lung tumor shrank by over 30 percent. By six months, imaging ...

Upon approval, the Test will be intended to help identify patients with NSCLC who may respond to treatment with Tagrisso® (Osimertinib), AstraZeneca’s third-generation EGFR-TKI treatment. Roger Moody, ...

Mount Laurel, N.J., United States: CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor ...

Similar results were seen in a pooled analysis of patients previously treated with osimertinib (ORR: 44.8%; median DOR: 6.9 months). Replimune is seeking approval of vusolimogene oderparepvec in ...